Biotech Breakthroughs — 2026-05-08

Top Breakthroughs This Week

1. Bioxodes Presents Positive Final Phase 2a Data for BIOX-101 in Intracerebral Hemorrhage

• Company / Institution: Bioxodes SA (Gosselies, Belgium)
• What happened: On May 6, 2026, Bioxodes announced final results from its Phase 2a clinical trial of BIOX-101, presented as a poster at the European Stroke Organisation Conference (ESOC 2026). The data confirmed the compound's breakthrough potential in treating intracerebral hemorrhage (ICH), a particularly lethal and treatment-resistant form of stroke. The company described the results as "affirming breakthrough potential."
• Indication / Target: Intracerebral hemorrhage (ICH); thrombotic and inflammatory diseases. ICH accounts for roughly 10–15% of all strokes and has no approved pharmacological treatment to limit hematoma expansion.
• Why it matters: ICH represents one of the largest unmet needs in cerebrovascular medicine, with 30-day mortality exceeding 40% and no drug approved to limit early hematoma growth. Positive Phase 2a data for BIOX-101 opens the door to a pivotal Phase 3 program. Bioxodes is a clinical-stage biopharmaceutical company focused on novel anti-thrombotic and anti-inflammatory therapies, and this readout meaningfully de-risks the asset.

2. Seaport Therapeutics and Hemab Raise Combined $556M in Fresh Biotech IPO Sprint

• Company / Institution: Seaport Therapeutics and Hemab Therapeutics (both priced IPOs in the week ending May 2, 2026)
• What happened: Two biotechs, Seaport Therapeutics and Hemab, raised a combined $556M in back-to-back IPOs, continuing a mini-surge of public market activity. With a trio of IPOs closing around the same period, the sector is now on track to complete roughly two dozen offerings in 2026—consistent with the pace seen in most years since 2022. Notably, median deal size for Q1 2026 IPOs reached $287.5 million, far surpassing prior-year comparables according to BioPharma Dive data.
• Indication / Target: Seaport focuses on neuropsychiatric disorders; Hemab targets bleeding disorders.
• Why it matters: The surge in IPO deal sizes—even at a modest pace of volume—signals that institutional investors are selectively rewarding novel mechanisms and differentiated clinical profiles. A $287.5M median IPO in Q1 2026 reflects elevated conviction in certain subsectors, particularly neuroscience and rare hematology. This capital formation is critical to funding the next wave of Phase 2 and Phase 3 trials.

3. Q1 2026 Biotech IPOs: Median Deal Size Hits $287.5M, Sector on Track for ~24 Offerings in 2026

• Company / Institution: Multiple companies; analysis by BioPharma Dive (published March 31, 2026—most recent comprehensive data available this week)
• What happened: Six biotech companies priced IPOs in Q1 2026, banking a median of $287.5 million per offering—a figure BioPharma Dive described as "far surpassing" what was observed over a similar timeframe in prior years. The market is on pace for approximately two dozen total IPOs in 2026. The year's first IPO was Aktis Oncology, which raised $318M in January to advance its pipeline of radiopharmaceuticals for cancer, following $346M in private funding from MPM BioImpact, Vida Ventures, and RA Capital.
• Indication / Target: Oncology (radiopharmaceuticals), neuropsychiatry, rare disease, and hematology among the leading therapeutic categories.
• Why it matters: The shift toward larger, more selective IPOs—rather than a flood of smaller offerings—reflects a maturing biotech capital market. Investors are prioritizing clinical-stage assets with differentiated mechanisms, and the radiopharmaceuticals space in particular (exemplified by Aktis) is attracting significant institutional capital as a next-generation oncology modality.

Regulatory Roundup

Based on available verified data from within the coverage window, the following actions are documented:

• FDA Novel Drug Approvals 2026 tracker — The FDA's official novel drug approvals page lists a May 1, 2026 entry in its running log for 2026, indicating continued regulatory activity. Full details of the specific May approval require direct verification at Drugs@FDA.

• Daratumumab + Hyaluronidase-fihj (Darzalex Faspro) / Janssen — Approved January 27, 2026 in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma. This label expansion cements Darzalex Faspro as a frontline standard-of-care option and significantly broadens the drug's commercial addressable market.

• Teclistamab + Daratumumab Hyaluronidase-fihj (Tec-Dara) / Janssen — Approved March 5, 2026 as the FDA's third approval under the National Priority Voucher Program, for adults with relapsed or refractory multiple myeloma who have received at least prior lines of therapy. The bispecific antibody combination marks a significant advance for heavily pretreated myeloma patients.

Therapeutic Modality Watch

Gene & Cell Therapy

• Personalized CRISPR on-demand pathway: The FDA's "plausible mechanism pathway" for bespoke gene-editing treatments, unveiled in February 2026, continues to draw attention in the field. The agency expects a flood of applications for individualized CRISPR medicines under this framework, which was designed to enable approval of therapies for ultra-rare or unique genetic conditions. Academic sites including Penn-CHOP, University of Wisconsin, and IGI-UCSF are among the first expected applicants.

• Aurora Therapeutics (CRISPR startup): Founded by scientist Fyodor Urnov (of "Baby KJ" fame) and venture capitalist Johnny Hu, Aurora Therapeutics launched in early January 2026 as one of the newest entrants in the personalized CRISPR medicines field. The company is building on the clinical proof-of-concept established by the first bespoke CRISPR treatment administered to Baby KJ.

• Aktis Oncology (radiopharmaceuticals): Aktis raised $318M in the first biotech IPO of 2026 (January 8), backed by MPM BioImpact, Vida Ventures, and RA Capital, to advance its pipeline of targeted radiopharmaceuticals for cancer. This represents a convergence of nuclear medicine and precision oncology—a distinct but rapidly growing advanced therapy segment.

Small Molecules & Biologics

• Daratumumab + VRd approval (myeloma frontline): Janssen's Darzalex Faspro gained frontline multiple myeloma approval January 27, 2026, with the quad regimen (Dara-VRd) setting a new benchmark for newly diagnosed patients. The subcutaneous formulation offers patient convenience advantages over intravenous daratumumab.

• Teclistamab/Dara bispecific combination (myeloma relapsed/refractory): The FDA's March 5, 2026 approval of Tec-Dara represents the first bispecific antibody combination to gain regulatory clearance in heavily pretreated myeloma, suggesting a new combinatorial paradigm for the disease.

• BIOX-101 (Bioxodes): Phase 2a positive results for this anti-thrombotic/anti-inflammatory agent in intracerebral hemorrhage are detailed above. The compound's mechanism targets both coagulation and inflammation pathways, a differentiated approach for ICH where hematoma expansion and secondary inflammation both drive poor outcomes.

Platform & Discovery Tech

• FDA real-time clinical trials pilot (AstraZeneca + Amgen): First announced April 28, 2026, the FDA is testing an innovative program in which cancer drug trials from AstraZeneca and Amgen will be monitored in real time—allowing the agency to shorten the interval between trial phases. This could meaningfully compress development timelines for oncology candidates if validated.

• Oricell Therapeutics Pre-IPO Funding: Chinese cell therapy developer Oricell completed a $110M pre-IPO round (April 10, 2026), bringing its total to over $110M ahead of a planned public offering. Investors included Vivo Capital, Qiming Venture Partners, E-Town Capital, and others, signaling continued global appetite for next-generation cell therapy platforms.

Business & Pipeline Moves

• Seaport Therapeutics IPO (~$278M) — Neuropsychiatry-focused Seaport priced its IPO in the week of May 2, 2026, as part of a combined $556M raise alongside Hemab. The company's focus on novel CNS mechanisms positions it within one of biotech's most capital-intensive but potentially lucrative spaces.

• Hemab Therapeutics IPO (~$278M) — Hemab, targeting rare bleeding disorders, co-priced its IPO alongside Seaport in the same week. Together the two deals signal continued investor interest in rare hematology and underscore the premium placed on differentiated mechanisms in competitive disease areas.

• Aktis Oncology IPO ($318M, January 2026) — Aktis raised $318M in 2026's first biotech IPO to advance its radiopharmaceutical oncology pipeline, backed by $346M in prior private funding from MPM BioImpact, Vida Ventures, and RA Capital. The offering set the tone for an elevated-median-deal-size year.

• Oricell Therapeutics $110M Pre-IPO Round (April 10, 2026) — The Chinese CAR-T/cell therapy developer completed its final private funding round before an anticipated IPO, backed by a consortium including Vivo Capital, Qiming, and a "leading global healthcare fund." The round signals continued international capital formation in advanced cellular therapies.

Analyst Take

• Dominant theme this week: Capital formation and clinical de-risking are converging. The week's biggest stories—BIOX-101 Phase 2a data, the Seaport/Hemab IPO sprint, and the broader Q1 2026 IPO median size story—all point to a market rewarding differentiated assets in unmet-need indications (ICH, bleeding disorders, CNS) with outsized investor confidence.

• Momentum shift: Radiopharmaceuticals gained significant ground as an oncology modality in early 2026, exemplified by Aktis's $318M IPO. The combination of targeted delivery, growing clinical validation, and commercial precedents (following Novartis's Lutathera and Pluvicto) is pulling capital toward this subsector at an accelerating pace.

• Risk signals: The FDA's real-time clinical trials pilot (AstraZeneca/Amgen) remains unproven. If the pilot exposes challenges in data integrity or regulatory review under continuous monitoring, it could complicate rather than accelerate development timelines. Additionally, biotech IPOs at elevated deal sizes carry the implicit risk of disappointing post-IPO performance if clinical milestones slip—a pattern that has repeatedly pressured the sector since 2022.

What to Watch Next Week

• FDA Novel Drug Approvals (ongoing): Monitor the FDA's updated novel drug approvals list for any new molecular entities or biologics approved in the week of May 5–8, 2026. The tracker was last updated with a May 1 entry—further activity is expected imminently.

• ESOC 2026 Stroke Conference presentations: Additional late-breaking data from the European Stroke Organisation Conference (where Bioxodes presented BIOX-101 results) may include competitive readouts in ICH and ischemic stroke. Investors tracking the cerebrovascular space should monitor for further clinical updates through mid-May.

• Biotech IPO pipeline: With the sector on track for ~24 IPOs in 2026 and two pricing in early May, additional companies are expected to test the public markets. The Fierce Biotech Fundraising Tracker and BioPharma Dive IPO tracker are the authoritative sources for forthcoming filings and pricings.

Reader Action Items

• For investors: Monitor Bioxodes (private; watch for Series B or licensing announcements) and the radiopharmaceuticals sector (Aktis, $RAD, $NVCR) following Aktis's strong IPO debut. The Phase 2a BIOX-101 data is a clear value-creation catalyst in an indication with no approved pharmacotherapy—partner interest from large-cap pharma is likely to follow.

• For operators & scientists: Read the full Bioxodes BIOX-101 Phase 2a data release in detail—it represents one of the few late-stage datasets in pharmacological ICH management and may inform future trial design. Full press release available at:

• For patient advocates: The FDA's approval of Tec-Dara (teclistamab + daratumumab) under the National Priority Voucher Program (March 5, 2026) is the most immediately actionable approval for patients. Heavily pretreated multiple myeloma patients who have exhausted prior lines now have access to a bispecific antibody combination that previously was unavailable as a regulatory-approved regimen. Patients and caregivers should discuss eligibility criteria with their hematologists.

1 sources

biospace.com

biospace.com